PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

NADH (Nicotinamide adenine dinucleotide, reduced) — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

In a randomized, double-blind crossover pilot study in 26 people with chronic fatigue syndrome, 8 responded to a stabilized oral form of NADH (the reduced form of nicotinamide adenine dinucleotide) against 2 on placebo. · pmid:10071523

Mechanism

In mice, NADH given by mouth, unlike nicotinamide or NAD+, did not raise urinary nicotinamide metabolites, and NADH was rapidly converted to an unidentified compound at stomach-like acidic pH. · pmid:16802695

Identity

PubChem CID 439153: Nadh, C21H29N7O14P2, 665.4 g/mol. · pubchem:439153

CAS registry number 58-68-4. · pubchem:439153

IUPAC name: [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate. · pubchem:439153

Where the evidence actually sits

Emerging50%
Preclinical only50%

Proportion of the 2 claims about NADH (Nicotinamide adenine dinucleotide, reduced) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. (1999) · emergingComparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH. (2006) · preclinical19992006

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for NADH (Nicotinamide adenine dinucleotide, reduced) yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested
    • Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. · pmid 10071523 · 1999
  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH. · pmid 16802695 · 2006

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.